EUVIMEDTutustu EUVIMEDiin
Übersichtsarbeit

The expanding incretin universe: from basic biology to clinical translation

Daniel J Drucker iD, Jens J Holst iD

Diabetologia · 2023-10 · 66 (10) · 1765-1779

DOI: 10.1007/s00125-023-05906-7 ↗

At a glance

Übersichtsarbeit in Diabetologia, published online on 2023-03-28. Written by Daniel J Drucker and 1 co-authors. Institution: Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada. drucker@lunenfeld.c…. Major MEDLINE topics: Incretins, Diabetes Mellitus, Type 2. Cited 245 times so far (Crossref); 174 references. Funded by: CIHR.

TiivistelmäSubjectsBibliografiset tiedotCiteRelated studies

Abstract (original language)

Incretin hormones, principally glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1(GLP-1), potentiate meal-stimulated insulin secretion through direct (GIP + GLP-1) and indirect (GLP-1) actions on islet β-cells. GIP and GLP-1 also regulate glucagon secretion, through direct and indirect pathways. The incretin hormone receptors (GIPR and GLP-1R) are widely distributed beyond the pancreas, principally in the brain, cardiovascular and immune systems, gut and kidney, consistent with a broad array of extrapancreatic incretin actions. Notably, the glucoregulatory and anorectic activities of GIP and GLP-1 have supported development of incretin-based therapies for the treatment of type 2 diabetes and obesity. Here we review evolving concepts of incretin action, focusing predominantly on GLP-1, from discovery, to clinical proof of concept, to therapeutic outcomes. We identify established vs uncertain mechanisms of action, highlighting biology conserved across species, while illuminating areas of active investigation and uncertainty that require additional clarification.

Subjects

MeSH terms (MEDLINE)

IncretinsDiabetes Mellitus, Type 2HumansGlucagon-Like Peptide 1Gastric Inhibitory PolypeptideBiology

Author keywords

Alzheimer’s diseaseDiabetesHeart failureIncretinNon-alcoholic steatosisObesityReview

Substances

IncretinsGlucagon-Like Peptide 1Gastric Inhibitory Polypeptide

Authors and institutions

  • Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada. drucker@lunenfeld.ca.
  • The Novo Nordisk Foundation Center for Basic Metabolic Research, Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.

ORCID profiles: Daniel J Drucker, Jens J Holst

Funding

  • CIHR

Cite

APA

Drucker, D. J., & Holst, J. J. (2023). The expanding incretin universe: from basic biology to clinical translation. Diabetologia, 66(10), 1765-1779. https://doi.org/10.1007/s00125-023-05906-7

Vancouver

Drucker DJ, Holst JJ. The expanding incretin universe: from basic biology to clinical translation. Diabetologia. 2023;66(10):1765-1779. doi:10.1007/s00125-023-05906-7

BibTeX
@article{Drucker2023,
  author = {Drucker, Daniel J and Holst, Jens J},
  title = {The expanding incretin universe: from basic biology to clinical translation},
  journal = {Diabetologia},
  year = {2023},
  volume = {66},
  number = {10},
  pages = {1765--1779},
  doi = {10.1007/s00125-023-05906-7}
}
Start for free →